A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Study of N91115 to Evaluate Safety and Pharmacokinetics in Patients With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

Trial Profile

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Study of N91115 to Evaluate Safety and Pharmacokinetics in Patients With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Cavosonstat (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Acronyms SNO4
  • Sponsors Alpine Immune Sciences; Nivalis Therapeutics
  • Most Recent Events

    • 25 Jul 2017 According to a Alpine Immune Sciences media release, Alpine Immune Sciences acquired Nivalis Therapeutics and the combined companies changed its name to Alpine Immune Sciences.
    • 16 May 2016 Status changed from active, no longer recruiting to completed according to Nivalis Therapeutics media release.
    • 07 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Feb 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top